<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-06-03T15:52:43Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/829949EF-6F4F-4ABC-AAEE-5C67852348C4" ns1:id="829949EF-6F4F-4ABC-AAEE-5C67852348C4"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/persons/12518AA1-3E48-430C-A26A-BD55ADDC021F" ns1:rel="PM_PER"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/65EAC07B-0B87-4CD5-9A0B-D12BCF975ECE" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/65EAC07B-0B87-4CD5-9A0B-D12BCF975ECE" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2020-02-29T00:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/2A9881AD-7B70-47DE-BA31-98956B8F8CBD" ns1:rel="FUND" ns1:start="2019-03-01T00:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">971627</ns2:identifier></ns2:identifiers><ns2:title>Novel anti-infective medical device</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>Small Business Research Initiative</ns2:grantCategory><ns2:leadFunder>Innovate UK</ns2:leadFunder><ns2:abstractText>Over 100 million people use urinary catheters in the world every year. However, these devices are the root cause for the most common healthcare infection in the world, catheter-associated urinary tract infections (CAUTIs). CAUTIs serious enough to require antibiotic treatment affect 24% of long-term patients, of which ~70% of the bacteria responsible show antimicrobial resistance, resulting in ~ 2,100 deaths in the UK annually. CAUTIs are typically treated by long-term courses of antibiotics but this contributes to the spread of deadly antimicrobial resistant bacteria. Clean Blue Limited is developing the solution: a catheter that prevents colonisation of bacteria without using any pharmaceuticals in order to reduce the current dependency on antibiotic treatment and the subsequent risk of AMR occurrence. The successful development and application of this new technology could improve patient care; save lives and millions of pounds for the NHS; and open up a new front in the fight against antibiotic resistant bacteria</ns2:abstractText></ns2:project>